Degree of Premenstrual Mood Cyclicity is Predictive of Elevated Tonic Interleukin-6 Levels in Women with Menstrually-Related Mood Disorder by Khatiwada, Priyenka Niju
 
 
 
 
 
 
Degree of Premenstrual Mood Cyclicity is Predictive of Elevated Tonic Interleukin-6 Levels in Women with 
Menstrually-Related Mood Disorder  
 
 
 
Priyenka Niju Khatiwada 
 
 
 
A thesis submitted to the faculty at the University of North Carolina at Chapel Hill in partial fulfillment of the 
requirements for the degree of ​Bachelor of Science in the biology department in the college of arts and 
sciences.  
 
 
 
Chapel Hill  
2016 
 
 
 
 
Approved: 
Samantha Meltzer-Brody, MD, MPH 
Lisa Tarantino, PhD 
Amy Shaub Maddox, PhD 
 
 
Abstract  
Menstrually-Related Mood Disorder (MRMD) is characterized by cyclical luteal phase onset of severe             
emotional symptoms with resolution during menses. Despite the symptomatic similarities with chronic anxiety             
and mood disorders, the menstrual cycle entrainment of symptoms in MRMD presents a unique challenge for                
treatment. More information about the pathophysiology of MRMD could help improve treatment options.             
Low-grade inflammation is implicated in the pathophysiology of some psychiatric disorders with symptom             
profiles similar to MRMD. We hypothesize that women with both (1) greater peripheral inflammation at baseline                
(​tonic​ inflammation), and (2) greater changes in inflammation in response to acute stress, will prospectively               
report a greater premenstrual elevation of symptoms relative to their own follicular baseline (i.e., greater               
cyclicity​ of symptoms). Women completed 2-4 months of daily symptom ratings. Our sample consisted of 51                
women meeting prospective criteria for MRMD on the basis of these daily ratings. For each woman, an                 
average premenstrual symptom elevation in several symptom domains was calculated for each women. Each              
woman then reported to the laboratory during the luteal phase of the menstrual cycle, and the participant’s                 
response to stress was measured in serum at baseline and during the Trier social stress test (TSST).                 
High-sensitivity ELISA kits were used to measure IL-6 levels as a marker of inflammation. Multilevel models in                 
SAS PROC MIXED (with time points nested within women) predicted IL-6 at each time point from (1) time, (2)                   
degree of cyclicity in each symptom, and (3) the interaction of cyclicity and time. In a sample of 51 women with                     
prospectively-confirmed MRMD, the degree of symptom cyclicity across several domains was positively            
correlated with elevated baseline levels of inflammation (IL-6). However, degree of symptom cyclicity was not               
associated with the degree of stress-related increase in inflammation during the TSST. This work provides the                
first evidence that prospectively-measured premenstrual symptom severity is associated with elevated tonic            
inflammation; this similarity to major depressive disorders may provide insights into prevention and treatment. 
  
Introduction 
Premenstrual Dysphoric Disorder (PMDD) is characterized by the recurrent onset of at least 5 symptoms, such                
as depression, anxiety, hopelessness, mood swings, and irritability, in the luteal phase of the menstrual cycle                
(Pearlstein and Steiner, 2008). PMDD results in psychological distress and impairment in the 3-8% of women                
who meet DSM-5 criteria of ​content, cyclicity, severity, and chronicity of symptoms​. Onset of emotional               
symptoms causing distress and impairment sufficient to warrant treatment, but failing to meet strict DSM-5               
criteria of PMDD is referred to in research contexts as menstrually-related mood disorder (MRMD; Halbreich et                
al., 2003). The psychosocial outcomes of these conditions result in significant distress that interferes with daily                
life. Current empirically-supported treatment options include SSRIs, prevention of ovulation with GnRH            
agonists, and psychotherapy. ​Selective serotonin reuptake inhibitors and initial oral contraceptives for the             
treatment of PMDD: effective but not enough (Halbreich et al., 2003). ​While a drospirenone pill with low                 
estrogen oral contraceptives has been shown to alleviate severe symptoms of PMDD for at least 3 months, it is                   
not known if it helps women with less severe symptoms or is just a better form of birth control (​Lopez, Kaptein,                     
and Helmerhorst, 2012)​. Neither SSRIs nor birth control pills were created explicitly for the treatment of                
PMDD/MRMD, but by expanding scientific knowledge about the pathophysiology of PMDD/MRMD a more             
effective treatment could be developed.  
 
Low-grade inflammation is implicated in the pathophysiology of various psychiatric disorders, including            
depression, that share common features with PMDD/ MRMD. Low-grade inflammation results from the             
stimulation of the pro-inflammatory cytokine network, which is activated commonly by injury as well as stress                
(Berk et al., 2013). Interleukins are critical messengers of the immune system, and interleukin-6 is involved in                 
the pro-inflammatory response. Innate immune cells persistently produce pro-inflammatory cytokines in           
response to continued stress, resulting in prolonged low-grade inflammation (​Dantzer, 2008)​. Inflammatory            
cytokine​s directly interact with pathophysiologic domains that are affected in depression including            
neurotransmitter metabolism, neuroendocrine function, and ​neural plasticity​. Activation of inflammatory          
pathways in the brain is believed to contribute to “decreased neurotrophic support and altered glutamate               
release/reuptake, as well as oxidative stress, leading to excitotoxicity and loss of glial elements, consistent with                
neuropathologic findings that characterize depressive disorders (​Miller, Maletic, Raison, 2009).​” Additionally,           
low-grade inflammation induces sickness behavior, which includes lethargy, depression, anxiety, loss of            
appetite, sleepiness, hyperalgesia, reduction in grooming and failure to concentrate (Kent, Bluthé, Kelley,             
Dantzer, 1992). ​Inflammatory markers have also been shown to increase during acute psychosocial stress              
(Steptoe, Hamer, Chida, 2007), and greater stress-related increases in inflammatory markers are associated             
with depression severity, feelings of social rejection, ​and higher ambulatory BP ​(Fagundes, Glaser, Hwang,              
Malarkey, Kiecolt-Glaser, 2013; Slavich, Way, Eisenberger, & Taylor, 2010; Brydon, Steptoe, 2005). Thus, it is               
possible that individual differences in tonic inflammatory immune function may play an etiologic role in               
development of MRMD/PMDD, increasing vulnerability for cyclical premenstrual inflammation and associated           
symptoms. Additionally, individual differences in the magnitude of stress-related inflammatory responses may            
also be risky, increasing the likelihood of premenstrual symptoms. 
 
The purpose of the present study is to assess whether (1) peripheral inflammation at baseline (referred to as                  
tonic​ inflammation), and (2) changes in inflammation in response to acute psychosocial stress predict the               
degree of (prospectively characterized) premenstrual increases in symptoms among women diagnosed with            
MRMD/PMDD. Because low-grade inflammation has been implicated in the onset and persistence of             
depressive disorders, we predicted that women with both (1) greater baseline levels of IL-6 at baseline, and (2)                  
greater IL-6 increases following stress would report greater premenstrual increases in symptoms.  
 
Methods  
I. General Procedure 
Women were recruited and screened prospectively for 2-4 cycles using the DRSP (​Daily Record of Severity                
Problems) ​and Carolina Premenstrual Assessment Scoring System (C-PASS) described below in Table 1.             
These prospective data were used to compute both (1) a woman’s average baseline follicular symptoms in                
each domain and (2) a woman’s average premenstrual symptoms in each domain. Women meeting              
prospective criteria for MRMD then underwent the TSST (Trier Social Stress Test) described below. During the                
TSST, IL-6 was measured 4 times in order to gather both baseline inflammation and 3 timepoints to measure                  
inflammatory reactivity to the stressor.  
II. Diagnostic and Prospective Data Methods and Procedure 
A. Daily Symptom Data Collection 
The Daily Record of Severity Problems form (DRSP form; Endicott, Nee, & Harrison, 2005) is a widely used,                  
well-validated prospective measure of daily ratings, allowing for the assessment of the four diagnostic              
dimensions. The DRSP contains 21 items, which fully cover the DSM-5 (2013) content, asking the rater to                 
indicate the daily severity of each symptom on a 6-point Likert scale (1 – Not at all, 2 – Minimal, 3 – Mild, 4 –                         
Moderate, 5 – Severe, 6 – Extreme). ​The DRSP (Endicott et al., 2006) was administered daily during                 
participation.  
B. The C-PASS Diagnostic Method 
The C-PASS is a recently-developed diagnostic protocol for making the DSM-5 diagnosis of PMDD using >=2                
months of daily ratings on the DRSP. It uses only the seven days prior to the onset of menses (days -7 to -1;                       
premenstrual phase) and the 7 days following average menstrual offset on day 4 (days 4 to 10; postmenstrual                  
phase) where day -1 represents the day prior to menstrual onset and day 1 represents menstrual onset. The                  
C-PASS requires that at least 3 out of 7 possible days of ratings be present in each phase from a given cycle;                      
cycles in which 4 or more daily diaries are missing from either the premenstrual or postmenstrual phases are                  
not scored. The C-PASS begins the diagnostic process by characterizing each DRSP item in each cycle                
(where a cycle is defined as a set of postmenstrual and premenstrual phases from two consecutive menstrual                 
cycles) using the four diagnostic dimensions as described in Table 1 (​relative symptom change:​ percent               
change from premenstrual to postmenstrual >=30%; ​absolute clearance​ : postmenstrual week maximum <=3;            
absolute severity​ : premenstrual week maximum >=4; and ​duration:​ severe premenstrual week days >=2).             
Next, diagnosis of PMDD at the level of the cycle is made by counting how many DSM-5 symptoms reach the                    
threshold on all four required dimensions (see Table 1; Total Symptoms must be >=5 for PMDD; no                 
requirement of Total Symptom number in MRMD) and whether a core symptom has been met (number of core                  
symptoms >=1). Note that the C-PASS counts the number of ​DSM-5 symptoms meeting criteria at this stage                 
rather than the number of ​DRSP items meeting criteria (see Table 1). Next, the C-PASS makes the diagnosis                  
of PMDD by counting the number of cycles meeting diagnostic criteria in a given woman (cycles meeting                 
criteria >=2). In the present study, the research diagnosis of MRMD (i.e., at least one emotional symptom met                  
for at least 2 cycles) was used. In addition, the C-PASS was used for each woman to calculate her average                    
percent premenstrual elevation (over their own follicular baseline) of each core symptom. These variables were               
used as indicators of ​cyclicity ​ of each symptom in each woman. 
C. Trier Social Stress Test​ ​(TSST) Protocol 
Each participant underwent the laboratory procedure during the luteal phase of the menstrual cycle, 5–12 days                
after a home urine ovulation test indicated that the luteinizing hormone had surged due to ovulation                
(corresponding to days 18–25 of an idealized 28-day cycle). Each participant assumed the role of a job                 
applicant and was individually introduced to a 3 person committee. Participants prepared a speech in 10                
minutes and then delivered her speech in 5 minutes. The committee responds with prepared questions. Then                
the subject subtracts the number 13 from 1,022 as fast and as accurately as possible, having to start over if                    
they make a mistake.  
D. Intravenous Blood Draw 
A research nurse inserted a butterfly needle into a forearm vein. A non-heparinized, multi-stop-cock system               
was employed, to allow the nurse to draw blood samples without the added stress involved in multiple                 
venipunctures. Once the needle was in place, a curtain was drawn to prevent the participant from viewing                 
blood sampling. A 15-minute recovery period followed the intravenous blood draw setup. Then samples were               
taken for baseline measures and 3 timepoints to measure inflammatory reactivity to the stressor during the                
TSST.  
E. IL-6 Assay 
Sera were frozen at −80◦ C and later thawed for analysis. Solid phase ELISA kits for ​human IL-6 immunoassay                   
(R&D Systems, Minneapolis, MN) were utilized to ​quantitate IL-6 levels in serum. After all reagents and                
standard dilutions were prepared, 100 µL of assay diluent was added to each well. Then 100 µL of serum from                    
each sample was added to each well and then incubated for 2 hours. Each well was aspirated a total of 4                     
times, 200 µL of conjugate was added and then incubated at room temperature for 2 hours. Each well was                   
aspirated and washed 4 times. Then 200 µL substrate solution was added to each well and incubated at room                   
temperature for 20 minutes. Finally, 50µL of stop solution was added to each well and read at 450 nm. IL-6                    
results were log10 transformed to achieve distributional normality within our sample, which is critical for               
statistical analysis.  
F. Analytic Plan Testing Hypothesis 
IL-6 data are structured such that 4 TSST ​samples are nested within ​women.​ Therefore, we utilized a                 
two-level regression model that accounts for this data structure. Hypotheses were tested as multilevel models               
in SAS PROC MIXED (SAS Institute, Inc, Cary, NC). Models (run separately for each of the 24 DRSP                  
symptoms) predicted IL-6 from the following predictors: (1) sample (baseline, 10 minutes post-TSST, 20              
minutes post-TSST, and 30 minutes post-TSST), (2) mean follicular baseline symptoms in a given domain, (3)                
the interaction of mean follicular symptoms with sample, (4) mean premenstrual symptoms in the same               
domain, and (5) the interaction of mean premenstrual symptoms with sample. ​Therefore, the main effects of                
premenstrual symptoms indicate the association of ​degree of premenstrual symptom increase over            
baseline with ​tonic levels of IL-6​ , whereas its interactions with sample indicate the association of               
degree of premenstrual symptom increase over baseline with the degree of ​IL-6 reactivity to the TSST​ .                
For increased clarity, standardized gamma weight estimates (as estimated in SAS PROC GLIMMIX) are              
presented. 
 
Results 
It is known that inflammation increases in individuals with major depressive disorders; however, it is not known                 
whether degree of symptom cyclicity predicts inflammatory response to stress or baseline levels of              
inflammation. Figure 1 A-D shows the average phase-level symptom means from the C-PASS for depression,               
anxiety, mood swings, and anger and interpersonal conflict. An average of symptom levels, in both women                
showing and not showing cyclicity for a given symptom, showed a linear increase from follicular baseline to                 
premenstrual baseline across all symptoms. 
  
In order to assess the relationship between degree of premenstrual symptom cyclicity and inflammation we               
measured symptoms and IL-6, a proxy to measure the severity of inflammation, for each woman. IL-6 values                 
underwent log10 transformation to achieve normality within the sample of 26 women and values were plotted                
against degree of symptom cyclicity. 
  
Consistent with predictions, a greater degree of symptom increase from the follicular baseline to the               
premenstrual phase was generally associated with elevated tonic level of IL-6. This was true for a variety of                  
symptoms; tonic IL-6 was predicted by cyclicity of hopelessness, worthlessness and guilt, mood swings,              
rejection sensitivity, anhedonia and loss of interest, physical symptoms, and life impairment (but not cyclicity of                
anxiety), difficulty concentrating, lethargy and fatigue, overwhelmed or couldn’t cope, work interference,            
hobbies and social activity interference, and relationship interference.  
  
Because the multilevel models revealed that mean levels of IL-6 across the TSST-- and not reactivity to the                  
TSST-- were predictive of symptom cyclicity, we chose to provide simpler scatterplot figures of this effect in                 
which we plotted individual IL-6 means against symptom cyclicity variables. As seen in Figure 2 A-H,                
consistent with predictions, elevated tonic level of IL-6 was positively correlated with a greater degree of                
symptom cyclicity (i.e., a greater symptom increase from follicular mean symptoms to premenstrual mean              
symptoms). This was true for a variety of symptoms; higher tonic IL-6 predicted greater cyclicity of                
hopelessness, worthlessness and guilt, mood swings, rejection sensitivity, anhedonia and loss of interest,             
physical symptoms, life impairment, difficulty concentrating, lethargy and fatigue, overwhelmed or couldn’t            
cope, work interference, hobbies and social activity interference, and relationship interference. With anxiety             
being the only symptom not predicted by tonic IL-6. 
  
In contrast to the robust associations between degree of symptom cyclicity and tonic IL-6, there were no                 
significant interactions between symptom cyclicity and IL-6 levels (all ps < .08); therefore, IL-6 reactivity to                
stress was neither positively nor negatively correlated with degree of premenstrual symptom cyclicity. 
 
Discussion 
The purpose of the present study was to assess whether peripheral inflammation at baseline, and in response                 
to acute psychosocial stress, predicted severity of prospectively-rated premenstrual symptoms in women            
diagnosed with MRMD. In women with prospectively-confirmed menstrual cycle entrainment of affective            
psychiatric symptoms (MRMD), degree of symptom cyclicity across several domains was positively correlated             
with elevated baseline levels of inflammation (Interleukin-6). We expected to observe higher stress-reactivity of              
inflammation in women with higher cyclicity; however, degree of symptom cyclicity was not associated with               
stress-reactivity of inflammation during a standardized psychosocial stressor.  
 
This work provides the first evidence that premenstrual symptom cyclicity is associated with elevated levels of                
low-grade inflammation similar to that found in major depressive disorder. Various psychiatric disorders are              
accompanied by low-grade inflammation. We found a relationship between higher stress-reactivity of            
inflammation in women with higher cyclicity because inflammation prompts sickness behavior, which includes             
lethargy, depression, loss of appetite, sleepiness, hyperalgesia, reduction in grooming, and failure to             
concentrate (Kent, Bluthé, Kelley, Dantzer, 1992). The results of the current study suggest that either               
persistent background inflammation or luteal increases in baseline inflammatory immune function is a part of               
the etiology of PMDD/MRMD. 
  
The lack of association of symptom cyclicity with inflammatory reactivity is notable. This may indicate a failure                 
of the HPA (Hypothalamic-Pituitary Axis) axis to reestablish homeostasis following repeated stressors among             
at-risk women, resulting in an elevated background level of inflammation and blunted, rather than overly               
reactive, inflammatory response to stress. Consistent with this notion, MRMD women with a history of trauma                
or other early life adversity show more severe symptom cyclicity and a stronger linkage of progesterone                
changes and symptoms (Eisenlohr-Moul et al., 2016). Since traumatic experiences are known to cause chronic               
inflammation via dysregulation of the HPA axis (Miller, Chen, & Parker, 2011), future work should examine                
whether these effects of traumatic experience in MRMD may be mediated by inflammatory processes.              
Consistent with previous work implicating inflammation specifically in a depressive pattern of behavior, results              
appeared particularly robust for depressive symptoms. IL-6 effectively induces inflammatory pathways in the             
brain altering the glutamate-glutamine cycle and inducing oxidative stress, which are consistent with             
neuropathologic findings that characterize depressive disorders (Miller, Maletic, Raison, 2009). 
  
The present work has a variety of potential clinical implications. Both psychotherapy and medications may               
reduce inflammation, both directly and indirectly. Currently treatment includes psychotherapy, oral           
contraceptives, and antidepressants; however, up to 50% of women fail to respond to these treatments               
(Halbreich, 2008), suggesting the need for alternative therapies. This study suggests that treatment using              
anti-inflammatory drugs might better serve the needs of patients. In a proof-of-concept study using 3 doses of                 
tumor necrosis factor (TNF) antagonists (which blocks the activity of inflammation-promoting TNF), a 12-week              
trial demonstrated that 62% of patients with high baseline inflammatory biomarker showed a ≥50% reduction in                
depression (HAM-D) scores (Raison, et al., 2013). Additionally, mindfulness-based stress reduction might            
reduce HPA stress reactivity, which might help the HPA axis better regulate chronic low-grade inflammation               
(Girdler, Nguyen, Bunevicius, Bunevicius, 2013). 
  
One limitation of this study is that it does not compare the impact of IL-6 on premenstrual symptoms in women                    
with and without MRMD; therefore, it cannot be determined if these effects are specific to women with MRMD.                  
However, this sort of difference in the effects of IL-6 on symptoms is not hypothesized; we expect that the                   
impact of low-grade inflammation on cyclical variations in symptoms would be similar for all women. Further,                
the use of a dimensional measure of symptom cyclicity means that a control group is not strictly necessary.                  
Second, our measure of “baseline” inflammation was taken premenstrually, so we cannot determine whether              
this index represents baseline premenstrual inflammation or the participant’s baseline inflammation across the             
entire cycle. Ultimately a longitudinal measurement of IL-6 alongside symptoms will be necessary to address               
this question. Future studies should examine inflammation and symptoms across the cycle in women with               
MRMD, and examine whether potential premenstrual increases in baseline inflammation mediate premenstrual            
symptom increases. 
  
The purpose of this study was to assess whether peripheral inflammation at baseline, and in response to acute                  
psychosocial stress, predicted the degree of prospectively rated premenstrual increases in symptoms among             
women diagnosed with MRMD. As predicted, degree of symptom cyclicity across several domains was              
positively correlated with elevated baseline levels of inflammation (Interleukin-6). However, degree of symptom             
cyclicity was not associated with stress-reactivity of inflammation during a standardized psychosocial stressor.             
These results suggest that chronic low-grade inflammation may play a role in the etiology of               
menstrually-related mood symptoms, just as in other major affective conditions. Depression presenting with             
low-grade inflammation has been treated using anti-inflammatory medications; given this evidence that MRMD             
symptoms may be influenced via similar pathways, anti-inflammatories may be a promising treatment to              
explore for MRMD. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Diagnostic Dimensions of DSM-5 Premenstrual Dysphoric Disorder 
DIAGNOSTIC DIMENSIONS Diagnosis Based on DRSP DSM-5 
Content Symptoms Core symptoms: 
felt depressed/sad/down/blue, 
felt hopeless, felt 
worthless/guilty, felt 
anxious/keyed up/on edge, had 
mood swings, was more 
sensitive to rejection/feelings 
were easily hurt, felt 
angry/irritable, had 
conflicts/problems with other 
people 
Secondary symptoms: 
less interest in usual activities, 
difficulty concentrating, 
lethargic/fatigue/tired/lack of 
energy, increased 
appetite/overate, specific food 
cravings, slept more/took 
naps/hard to get up, trouble 
getting to sleep/staying asleep, 
felt overwhelmed/couldn’t cope, 
felt out of control, breast 
tenderness, breast swelling/felt 
bloated/weight gain, headache, 
joint or muscle pain 
Impairment symptoms: 
“Less productivity at work, 
school, home or in daily routine” 
“Interference with hobbies or 
social activities (avoid, do less)” 
“Interference with relationships” 
Criterion B​: 
affective lability, 
irritability/anger/increased 
interpersonal conflicts, 
depressed mood/feelings of 
hopelessness/self-deprecati
ng thoughts, 
anxiety/tension/feelings of 
being keyed up/on edge 
Criterion C​: 
decreased interest, difficulty 
in concentration, 
lethargy/easy fatigability/lack 
of energy, change in appetite, 
hypersomnia/insomnia, 
overwhelmed/out of control, 
physical symptoms (breast 
tenderness, muscle pain, 
bloating, weight gain) 
Number MRMD 
≥ 1 ​core 
symptom 
  
PMDD 
≥ 1 ​core​ symptom 
≥ 5 total 
symptoms 
Criterion A: 
A total of 5 [at least (one or 
more) of each subgroup] 
Cyclicity Relative 
Symptom 
Change 
30% (relative to range of scale 
used) decrease from 
pre-menstrual week 
(days -7 à -1) to postmenstrual 
week (days 4 à 10) where 
1=menstrual onset 
Criterion A: 
“…present in the week 
before menses…improve 
within a few days after the 
onset of menses” 
Absolute 
Symptom 
Clearance 
Symptoms must not exceed 3 on 
any day during days 4 à 10 
Criterion A: 
“​minimal or absent​ in the 
week postmenses” 
  
Postmenses = following 
menstrual onset 
Clinical 
Significance 
Absolute 
Severity 
4 or more (on a Likert-scale from 
1 to 6) 
Criterion D: 
“symptoms are associated 
with clinically significant 
distress ​OR​ interference 
with work, school, usual 
social activities, or 
relationships with others” 
Duration At least 2 days (doesn’t have to 
be consecutive) 
Criterion D: 
“in the final week before the 
onset of menses” 
Not Simply Cyclicity of 
Other Disorder 
Rule out dysmenorrhea using 
prospective ratings. 
Rule out mood and anxiety 
disorder with SCID-1. 
Rule out Borderline Personality 
Disorder with SCID-2. 
Criterion E: 
“not merely an exacerbation 
of the symptoms of another 
disorder.” 
“Key differential diagnoses​: 
dysmenorrhea, bipolar 
disorder, MDD, dysthymia, 
and BPD.” 
Chronicity ≥ 2 symptomatic months 
  
Criterion A and F: 
“In the majority of menstrual 
cycles…” 
“…should be confirmed by 
prospective daily ratings 
during at least two 
symptomatic cycles.” 
Table 2. Sample Descriptive Information (N = 54) 
Variable Mean (SD) 
n (%) 
Age 38.11 (6.75) 
Race   
White 35 (65%) 
Black 16 (30%) 
Latina 2 (4%) 
Mixed or Other 1 (1%) 
Education Level   
High School 2 (4%) 
Trade School 3 (6%) 
Some College 13 (24%) 
College Grad 15 (28%) 
Graduate/Professional 21 (38%) 
Average Cycle Length in Days 29.42 (4.39) 
Average Phase-Level Symptom 
Means in Key Domains 
Follicular 
Baseline 
Premenstrual 
Depression 1.55 (.60) 2.73 (.99) 
Anxiety 1.59 (.58) 3.11 (1.15) 
Mood Swings 1.56 (.56) 3.12 (1.05) 
Anger and Interpersonal 
Conflict 
1.52 (.48) 3.25 (1.09) 
Physical Symptoms 1.20 (.46) 2.87 (1.45) 
Relationship Interference 1.29        .42) 2.56 (1.05) 
 Note.​  Standard Deviations and Percentages in Parentheses 
 
Figure 1 A-D: Average Phase-Level Symptom Means for Key Domains (Depression Anxiety, Mood 
Swings, and Anger and Interpersonal Conflict) at Follicular Baseline and Premenstrual  
An average of symptom levels, in both women showing and not showing cyclicity for a given symptom, showed                  
a linear increase from follicular baseline to premenstrual baseline across all symptoms.  
 
 
 
 
Figure 2 A-I: Degree of Symptom Cyclicity vs. Baseline IL-6  
Consistent with predictions, a greater degree of symptom increase from the follicular baseline to the               
premenstrual phase was generally associated with elevated ​tonic​ level of IL-6. This was true for a variety of                  
symptoms; tonic IL-6 was predicted by cyclicity of hopelessness, worthlessness and guilt, mood swings,              
rejection sensitivity, anhedonia and loss of interest, physical symptoms, and life impairment (but not cyclicity of                
anxiety), difficulty concentrating, lethargy and fatigue, overwhelmed or couldn’t cope, work interference,            
hobbies and social activity interference, and relationship interference.  
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